Biogen Inc (BIIB)

Precedente Chiudi:

$213.51

Aprire:

$215.3

Volume 24 ore:

279.81K

Capitalizzazione di mercato:

$31.09B

Reddito:

$9.66B

Utile/perdita netta:

$1.17B

Rapporto P/E:

11.75

EPS:

18.37

Flusso di cassa netto:

$1.28B

1 W Prestazione:

+3.18%

1M Prestazione:

+4.44%

6M Prestazione:

-13.61%

1 anno Prestazione:

-30.70%

Intervallo 1D:

$213.11

$215.93

Portata 52W:

$189.44

$319.76

Biogen Inc Stock (BIIB) Company Profile

Nome

Biogen Inc

Settore

Healthcare (1222)

Industria

Drug Manufacturers - General (18)

Telefono

617-679-2000

Indirizzo

225 Binney Street, Cambridge, MA

Dipendente

7,300

Cinguettio

@biogen

Prossima data di guadagno

2024-04-24

Ultimi documenti SEC

BIIB's Discussions on Twitter

Biogen Inc Stock (BIIB) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-02-14	Reiterato	Needham	Buy
2024-02-14	Downgrade	Wells Fargo	Overweight → Equal Weight
2024-01-24	Downgrade	UBS	Buy → Neutral
2023-12-20	Ripresa	Cantor Fitzgerald	Overweight
2023-12-07	Aggiornamento	Raymond James	Mkt Perform → Outperform
2023-09-06	Iniziato	HSBC Securities	Buy
2023-07-27	Iniziato	Scotiabank	Sector Outperform
2023-07-24	Reiterato	UBS	Buy
2023-05-01	Aggiornamento	Guggenheim	Neutral → Buy
2023-04-17	Aggiornamento	Piper Sandler	Neutral → Overweight
2022-10-26	Aggiornamento	Goldman	Neutral → Buy
2022-10-13	Aggiornamento	Stifel	Hold → Buy
2022-10-07	Aggiornamento	Argus	Hold → Buy
2022-09-28	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2022-09-28	Aggiornamento	Mizuho	Neutral → Buy
2022-09-28	Aggiornamento	Robert W. Baird	Neutral → Outperform
2022-04-18	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2022-03-08	Downgrade	Stifel	Buy → Hold
2022-03-03	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2022-02-04	Downgrade	BMO Capital Markets	Outperform → Market Perform
2022-02-04	Reiterato	Barclays	Equal Weight
2022-02-04	Reiterato	BofA Securities	Neutral
2022-02-04	Reiterato	Cowen	Outperform
2022-02-04	Reiterato	Morgan Stanley	Overweight
2022-02-04	Reiterato	Needham	Buy
2022-02-04	Reiterato	Oppenheimer	Outperform
2022-02-04	Reiterato	RBC Capital Mkts	Sector Perform
2022-02-04	Reiterato	Robert W. Baird	Neutral
2022-02-04	Reiterato	Wedbush	Neutral
2022-02-04	Reiterato	Wells Fargo	Equal Weight
2022-02-04	Reiterato	Wolfe Research	Peer Perform
2022-01-13	Downgrade	Guggenheim	Buy → Neutral
2022-01-12	Downgrade	Piper Sandler	Overweight → Neutral
2021-12-10	Ripresa	Raymond James	Mkt Perform
2021-12-09	Ripresa	Wells Fargo	Equal Weight
2021-12-06	Iniziato	Goldman	Neutral
2021-11-19	Iniziato	BMO Capital Markets	Outperform
2021-09-23	Iniziato	Needham	Buy
2021-06-18	Aggiornamento	Piper Sandler	Neutral → Overweight
2021-06-14	Reiterato	Truist	Buy
2021-06-11	Aggiornamento	Bernstein	Mkt Perform → Outperform
2021-06-10	Aggiornamento	UBS	Neutral → Buy
2021-06-08	Aggiornamento	Atlantic Equities	Underweight → Neutral
2021-06-08	Reiterato	Barclays	Equal Weight
2021-06-08	Aggiornamento	Citigroup	Sell → Neutral
2021-06-08	Reiterato	H.C. Wainwright	Buy
2021-06-08	Reiterato	Jefferies	Buy
2021-06-08	Reiterato	Morgan Stanley	Overweight
2021-06-08	Reiterato	RBC Capital Mkts	Sector Perform
2021-06-08	Aggiornamento	Robert W. Baird	Underperform → Neutral
2021-06-08	Reiterato	Stifel	Buy
2021-06-08	Aggiornamento	William Blair	Mkt Perform → Outperform
2021-06-07	Aggiornamento	BofA Securities	Underperform → Neutral
2021-06-07	Aggiornamento	Cowen	Market Perform → Outperform
2021-06-07	Aggiornamento	Raymond James	Underperform → Mkt Perform
2021-02-05	Downgrade	DZ Bank	Buy → Hold
2021-01-29	Aggiornamento	Stifel	Hold → Buy
2020-11-10	Aggiornamento	DZ Bank	Hold → Buy
2020-11-09	Downgrade	Atlantic Equities	Neutral → Underweight
2020-11-09	Downgrade	BofA Securities	Neutral → Underperform
2020-11-09	Downgrade	Cowen	Outperform → Market Perform
2020-11-09	Reiterato	H.C. Wainwright	Buy
2020-11-04	Aggiornamento	BofA Securities	Underperform → Neutral
2020-11-04	Aggiornamento	Jefferies	Hold → Buy
2020-11-04	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2020-10-28	Iniziato	UBS	Neutral
2020-07-27	Aggiornamento	Morgan Stanley	Underweight → Overweight
2020-06-22	Downgrade	Barclays	Overweight → Equal Weight
2020-06-22	Reiterato	RBC Capital Mkts	Sector Perform
2020-06-09	Downgrade	Bernstein	Outperform → Mkt Perform
2020-04-23	Downgrade	Citigroup	Neutral → Sell
2020-04-23	Downgrade	Raymond James	Mkt Perform → Underperform
2020-03-31	Iniziato	Wolfe Research	Peer Perform
2020-02-27	Iniziato	Barclays	Overweight
2020-01-27	Aggiornamento	Canaccord Genuity	Hold → Buy
2019-12-13	Aggiornamento	Credit Suisse	Underperform → Neutral
2019-12-02	Downgrade	Robert W. Baird	Neutral → Underperform

Mostra tutto

Biogen Inc Borsa (BIIB) Ultime notizie

Biogen Reports Progress on Corporate Responsibility Priorities

GlobeNewswire Inc.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Zacks Investment Research

The Analyst Landscape: 27 Takes On Biogen

Benzinga

Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates

Zacks Investment Research

The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals

Zacks Investment Research

Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX

Zacks Investment Research

Biogen Inc Azioni (BIIB) Dati Finanziari

Biogen Inc (BIIB) Reddito 2024

Biogen Inc (BIIB) Reddito netto 2024

Biogen Inc (BIIB) Flusso di cassa 2024

Biogen Inc (BIIB) Utile per azione 2024

Biogen Inc Azioni (BIIB) insider trading